However, increases in SPAG6, PER1, NKX2-6 and ITIH5 promoter methylation may not be confined to breast cancer and therefore needs to be tested in non-breast cancer patients such as colorectal- and lung cancer patients, the second and third most common cancers in women [1]. Here, NKX2-6 is linked to cancer.